News summaryThe Motley FoolNov 7, 2026, 07:31 PM
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Ginkgo Bioworks announced a strategic transition toward commercializing autonomous laboratory hardware and cloud data services. [[fact:fact-cvyhkh0u1]] The company’s CEO said Novo Nordisk selected Ginkgo to build an autonomous lab at its new R&D site in Waltham. [[fact:fact-11skag5lx]] The CFO said that at quarter-end, Ginkgo had $285 million in cash, cash equivalents, and marketable securities, no bank debt, and another $86 million in restricted cash, cash equivalents, and marketable securities. [[fact:fact-3b5vud5ok]] The CEO said Ginkgo cut spending while continuing major R&D investments in autonomous labs, AI, and laboratory robotics, and said those investments had paid off. [[fact:fact-nky3jqmwm]]